KT182 is primarily utilized in research settings as a potent and selective inhibitor of the kinase enzyme TBK1 (TANK-binding kinase 1). Its application is significant in the study of cellular signaling pathways, particularly those involving inflammation, immunity, and cancer. Researchers employ KT182 to investigate the role of TBK1 in various diseases, including autoimmune disorders and certain types of tumors, where TBK1 activity is often dysregulated. By inhibiting TBK1, KT182 helps elucidate the enzyme's function and its potential as a therapeutic target. Additionally, KT182 is used in preclinical studies to assess the efficacy of TBK1 inhibition in reducing tumor growth or modulating immune responses, providing valuable insights for drug development.